MedTrace Logo

Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity

NCT00689208 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2009-03-13

No results posted yet for this study

Summary

The present study on pharmacological intervention in autonomic nervous dysregulation(parasympathetic dysfunction,) regarding insulin resistance, is a concept testing in humans tohelp identify potential new pharmacological target sites in the central nervous system.

Conditions

Interventions

DRUG

Atropine

10 ug/kg bolus, 4 ug/kg/h infusion

DRUG

Physostigmine

0,12ug/kg/min

DRUG

Placebo Sodium

Sponsors & Collaborators

Principal Investigators

  • Per-Anders Jansson, prof · Lundberg Laboratory for diabetic research, Sahlgrenska Universitetssjukhuset Göteborg, Sweden

  • Jan Eriksson, MSD · Clinical Cardiovascular gastrointestinal departmentAstraZeneca R&D Mölnda Swedenl

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-10-31
Completion
2008-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689208 on ClinicalTrials.gov